Hormone Replacement Therapy Prescription after Premature Surgical Menopause.


Journal

Journal of minimally invasive gynecology
ISSN: 1553-4669
Titre abrégé: J Minim Invasive Gynecol
Pays: United States
ID NLM: 101235322

Informations de publication

Date de publication:
Historique:
received: 20 12 2019
revised: 05 03 2020
accepted: 05 03 2020
pubmed: 17 3 2020
medline: 5 2 2021
entrez: 17 3 2020
Statut: ppublish

Résumé

To assess hormone replacement therapy (HRT) prescription pattern in patients undergoing premature surgical menopause on the basis of surgical indication. Retrospective cohort study. Academic tertiary care center. Surgically menopausal patients aged ≤45 years who underwent a minimally invasive hysterectomy with salpingo-oophorectomy. HRT prescription in the 6-week postoperative period. A total of 63 patients met inclusion criteria. Of these, 52% (n = 33) were prescribed HRT in the 6-week postoperative period. Indications for surgical menopause included pelvic pain or endometriosis (31.7%), gynecologic malignancy (20.6%), BRCA gene mutation (17.4%), breast cancer (9.5%), Lynch syndrome (4.8%), and other (15.8%). In total, 80% of patients with pelvic pain, 25% with gynecologic malignancies, 45% with BRCA gene mutations, 33.3% with breast cancer, and 66.6% with Lynch syndrome used HRT postoperatively. In patients who used HRT postoperatively, 76% were offered preoperative HRT counseling. This is in contrast with those patients who did not use HRT postoperatively, of whom only 33% were offered HRT counseling (p <.001). Perioperative complications were not predictive of HRT use postoperatively. In patients who did not use HRT postoperatively, 13.3% used alternative nonhormonal therapy. In patients who underwent premature surgical menopause, 52% used HRT postoperatively. Patients with pelvic pain and Lynch syndrome were more likely to use HRT, whereas those with gynecologic or breast malignancies and BRCA gene mutations were less likely to use HRT. Preoperative HRT counseling was associated with postoperative HRT use.

Identifiants

pubmed: 32173578
pii: S1553-4650(20)30124-2
doi: 10.1016/j.jmig.2020.03.002
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1618-1623

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020. Published by Elsevier Inc.

Auteurs

Nisha Garg (N)

Department of Obstetrics and Gynecology, University of California, Irvine (Dr. Garg).

Sadikah Behbehani (S)

Department of Obstetrics and Gynecology, University of California, Riverside (Dr. Behbehani), California. Electronic address: Sadikah.behbehani@mail.mcgill.ca.

Heidi Kosiorek (H)

Department of Health Sciences Research, Mayo Clinic Arizona, Scottsdale (Ms. Kosiorek).

Megan Wasson (M)

Department of Gynecology, Mayo Clinic Arizona, Phoenix (Dr. Wasson), Arizona.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH